Plus Therapeutics (NASDAQ:PSTV) Earns Buy Rating from Analysts at D. Boral Capital

D. Boral Capital initiated coverage on shares of Plus Therapeutics (NASDAQ:PSTV) in a research note issued to investors on Monday morning, MarketBeat reports. The brokerage issued a buy rating and a $9.00 target price on the stock.

PSTV has been the subject of a number of other reports. Ascendiant Capital Markets lowered their target price on shares of Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating for the company in a research note on Monday, December 9th. HC Wainwright restated a “buy” rating and issued a $8.00 price objective on shares of Plus Therapeutics in a report on Tuesday, November 26th.

Plus Therapeutics Trading Down 8.4 %

Shares of PSTV opened at $0.51 on Monday. The firm has a market capitalization of $3.01 million, a P/E ratio of -0.20 and a beta of 0.73. Plus Therapeutics has a 12-month low of $0.24 and a 12-month high of $2.67. The firm has a fifty day moving average price of $1.09 and a 200-day moving average price of $1.24.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.